BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

271 related articles for article (PubMed ID: 36604228)

  • 1. The Value of Myocardial Fibrosis Parameters Derived from Cardiac Magnetic Resonance Imaging in Risk Stratification for Patients with Hypertrophic Cardiomyopathy.
    Yu T; Cai Z; Yang Z; Lin W; Su Y; Li J; Xie S; Shen J
    Acad Radiol; 2023 Sep; 30(9):1962-1978. PubMed ID: 36604228
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prediction of the estimated 5-year risk of sudden cardiac death and syncope or non-sustained ventricular tachycardia in patients with hypertrophic cardiomyopathy using late gadolinium enhancement and extracellular volume CMR.
    Avanesov M; Münch J; Weinrich J; Well L; Säring D; Stehning C; Tahir E; Bohnen S; Radunski UK; Muellerleile K; Adam G; Patten M; Lund G
    Eur Radiol; 2017 Dec; 27(12):5136-5145. PubMed ID: 28616729
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Quantitative diffusion-weighted magnetic resonance imaging in the assessment of myocardial fibrosis in hypertrophic cardiomyopathy compared with T1 mapping.
    Wu LM; Chen BH; Yao QY; Ou YR; Wu R; Jiang M; Hu J; An DA; Xu JR
    Int J Cardiovasc Imaging; 2016 Aug; 32(8):1289-97. PubMed ID: 27198892
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Radiomics of Late Gadolinium Enhancement Reveals Prognostic Value of Myocardial Scar Heterogeneity in Hypertrophic Cardiomyopathy.
    Fahmy AS; Rowin EJ; Jaafar N; Chan RH; Rodriguez J; Nakamori S; Ngo LH; Pradella S; Zocchi C; Olivotto I; Manning WJ; Maron M; Nezafat R
    JACC Cardiovasc Imaging; 2024 Jan; 17(1):16-27. PubMed ID: 37354155
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The value of cardiac magnetic resonance and distribution of late gadolinium enhancement for risk stratification of sudden cardiac death in patients with hypertrophic cardiomyopathy.
    Klopotowski M; Kukula K; Malek LA; Spiewak M; Polanska-Skrzypczyk M; Jamiolkowski J; Dabrowski M; Baranowski R; Klisiewicz A; Kusmierczyk M; Jasinska A; Jarmus E; Kruk M; Ruzyllo W; Witkowski A; Chojnowska L
    J Cardiol; 2016 Jul; 68(1):49-56. PubMed ID: 26363820
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic significance of late gadolinium enhancement on cardiac magnetic resonance in patients with hypertrophic cardiomyopathy.
    He D; Ye M; Zhang L; Jiang B
    Heart Lung; 2018; 47(2):122-126. PubMed ID: 29174363
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The amount of late gadolinium enhancement outperforms current guideline-recommended criteria in the identification of patients with hypertrophic cardiomyopathy at risk of sudden cardiac death.
    Freitas P; Ferreira AM; Arteaga-Fernández E; de Oliveira Antunes M; Mesquita J; Abecasis J; Marques H; Saraiva C; Matos DN; Rodrigues R; Cardim N; Mady C; Rochitte CE
    J Cardiovasc Magn Reson; 2019 Aug; 21(1):50. PubMed ID: 31412875
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Entropy of left ventricular late gadolinium enhancement and its prognostic value in hypertrophic cardiomyopathy a new CMR assessment method.
    Zhao X; Jin F; Wang J; Zhao X; Wang L; Wei H
    Int J Cardiol; 2023 Feb; 373():134-141. PubMed ID: 36395920
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association between myocardial hypoxia and fibrosis in hypertrophic cardiomyopathy: analysis by T2* BOLD and T1 mapping MRI.
    Ando K; Nagao M; Watanabe E; Sakai A; Suzuki A; Nakao R; Ishizaki U; Sakai S; Hagiwara N
    Eur Radiol; 2020 Aug; 30(8):4327-4336. PubMed ID: 32211964
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The relationship between myocardial fibrosis detected by cardiac magnetic resonance and Tp-e interval, 5-year sudden cardiac death risk score in hypertrophic cardiomyopathy patients.
    Riza Demir A; Celik Ö; Sevinç S; Uygur B; Kahraman S; Yilmaz E; Cemek M; Onal Y; Erturk M
    Ann Noninvasive Electrocardiol; 2019 Sep; 24(5):e12672. PubMed ID: 31152489
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic value of myocardial extracellular volume fraction evaluation based on cardiac magnetic resonance T1 mapping with T1 long and short in hypertrophic cardiomyopathy.
    Li Y; Liu X; Yang F; Wang J; Xu Y; Fang T; Pu L; Zhou X; Han Y; Chen Y
    Eur Radiol; 2021 Jul; 31(7):4557-4567. PubMed ID: 33449190
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [The value of cardiac MRI in the risk stratification in patients with hypertrophic cardiomyopathy].
    Wang JX; Yang SJ; Ma X; Yu SQ; Dong ZX; Xiang XR; Wei ZX; Cui C; Yang K; Chen XY; Lu MJ; Zhao SH
    Zhonghua Xin Xue Guan Bing Za Zhi; 2023 Jun; 51(6):619-625. PubMed ID: 37312480
    [No Abstract]   [Full Text] [Related]  

  • 13. MRI T1 Mapping in Hypertrophic Cardiomyopathy: Evaluation in Patients Without Late Gadolinium Enhancement and Hemodynamic Obstruction.
    Xu J; Zhuang B; Sirajuddin A; Li S; Huang J; Yin G; Song L; Jiang Y; Zhao S; Lu M
    Radiology; 2020 Feb; 294(2):275-286. PubMed ID: 31769741
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ESC sudden-death risk model in hypertrophic cardiomyopathy: Incremental value of quantitative contrast-enhanced CMR in intermediate-risk patients.
    Hinojar R; Zamorano JL; Gonzalez Gómez A; Plaza Martin M; Esteban A; Rincón LM; Portugal JC; Jimenez Nácher JJ; Fernández-Golfín C
    Clin Cardiol; 2017 Oct; 40(10):853-860. PubMed ID: 28614597
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Myocardial extracellular volume fraction measurements with MOLLI 5(3)3 by cardiovascular MRI for the discrimination of healthy volunteers from dilated and hypertrophic cardiomyopathy patients.
    Cui Y; Chen Y; Cao Y; Liu J; Song J; Zhang S; Kong X; Han P; Shi H
    Clin Radiol; 2019 Sep; 74(9):732.e9-732.e16. PubMed ID: 31122714
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic value of late gadolinium enhancement in clinical outcomes for hypertrophic cardiomyopathy.
    Green JJ; Berger JS; Kramer CM; Salerno M
    JACC Cardiovasc Imaging; 2012 Apr; 5(4):370-7. PubMed ID: 22498326
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic Value of LGE-CMR in HCM: A Meta-Analysis.
    Weng Z; Yao J; Chan RH; He J; Yang X; Zhou Y; He Y
    JACC Cardiovasc Imaging; 2016 Dec; 9(12):1392-1402. PubMed ID: 27450876
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A novel cardiac magnetic resonance-based personalized risk stratification model in dilated cardiomyopathy: a prospective study.
    Zhou D; Zhu L; Wu W; Zhuang B; He J; Xu J; Yang W; Wang Y; Li S; Sun X; Sharma P; Liu G; Sirajuddin A; Arai A; Zhao S; Lu M
    Eur Radiol; 2024 Jun; 34(6):4053-4064. PubMed ID: 37950081
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Endogenous T1ρ cardiovascular magnetic resonance in hypertrophic cardiomyopathy.
    Thompson EW; Kamesh Iyer S; Solomon MP; Li Z; Zhang Q; Piechnik S; Werys K; Swago S; Moon BF; Rodgers ZB; Hall A; Kumar R; Reza N; Kim J; Jamil A; Desjardins B; Litt H; Owens A; Witschey WRT; Han Y
    J Cardiovasc Magn Reson; 2021 Oct; 23(1):120. PubMed ID: 34689798
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Clinical Prognosis of Presence and Location of Late Gadolinium Enhancement by Cardiac Magnetic Resonance Imaging in Patients with Hypertrophic Cardiomyopathy: a Single-Center Cohort Study.
    Li X; Lai L; Luo R; Yang H; Ma H; Yang Z; Zhao S; Su W; Hua W
    J Cardiovasc Transl Res; 2021 Oct; 14(5):1001-1016. PubMed ID: 33629154
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.